ypertension affects approximately two-thirds of patients with diabetes mellitus (DM). Moreover, it synergistically increases cardiovascular morbidity and mortality. It is interesting to note that there is evidence to suggest that controlling blood pressure (BP) will reduce more cardiovascular disease (CVD) events than glycemic control alone.
Use of 24-hour ambulatory monitoring of BP allows for the capture of other important information, more specifically, the frequently reported excess incidence of blunted nocturnal decline in BP and nighttime hypertension in blacks with its associated excess morbidity and mortality. Ferdinand et al show that 25 mg of EMPA significantly reduces nighttime BP by 6 mm Hg. Thus, EMPA may be an effective agent to target nighttime hypertension.
In this issue, the effects of EMPA on nocturnal BP are specifically addressed in the report by Kario et al. 6 The investigators recruited Japanese patients with DM and uncontrolled nighttime BP on therapy with reninangiotensin-aldosterone system blockade. Kario et al posit that Japanese patients with DM and with nighttime hypertension were more likely to be salt sensitive and might derive particular benefit from treatment with EMPA. Although the primary aim of the trial was not achieved, in that there was not a significant reduction in the nighttime BP with 10 mg of EMPA in comparison with the placebo control group after 12 weeks of observation, the investigators observed significant reductions in 24-hour mean SBP of 7.7 mm Hg (and significant reductions in several other BP parameters). These results are consistent with Ferdinand et al. Kario et al had no preliminary data on which to calculate study power for the primary aim (nighttime SBP reduction). They expected a nighttime reduction of 5 mm Hg, but observed only a 4.7-mm Hg reduction. The observation period of 12 weeks was adequate to show an effect of 10 mg of EMPA, whereas Ferdinand et al found additional BP reduction between 12 and 24 weeks of observation using the 25-mg dose.
Kawasoe et al 7 investigated putative mechanisms of the BP-lowering effect of SGLT-2 inhibitors using 24-hour urinary collections and comparing the changes in urinary data with changes in SBP at baseline, 2 weeks, 1 month, and 6 months of administration of the various SGLT-2 inhibitors in outpatients from the Uenomachi-Kajiya Clinic (Kagoshima, Japan). The investigators found that SBP was significantly decreased at 1 month after administration of SGLT-2 inhibitors. The decrease in SBP at 1 month was accompanied by an increase in urinary volume and urinary excretion of both glucose and sodium. However, SBP continued to decrease up to 6 months after administration of SGLT-2 inhibitors. In contrast with the observations at 1 month, the decrease in SBP at 6 months was not correlated with increases in urinary glucose excretion. Instead, the 6-month SBP reduction was correlated with the increase in urinary sodium excretion, suggesting that the BP-lowering effect of SGLT-2 inhibitors at 6 months derives mainly from plasma volume reduction because of a natriuretic effect. These observations suggest that SGLT-2 inhibitors may exert both acute and longer-term effects on BP. It is possible that the results reported by both Ferdinand and Kario may have been more robust with additional follow-up time.
Before the 2 current reports in this issue of Circulation, the magnitude of BP reduction in previous trials with SGLT-2 inhibitors in diabetic populations with and without hypertension was much less robust. Baker et al 8 performed a meta-analysis of randomized, controlled trials to investigate the effects of SGLT-2 inhibitors on 24-hour ambulatory BP. SGLT-2 inhibitors significantly reduce 24-hour ambulatory systolic and diastolic BP by −3.76 mm Hg (95% CI, −4.23 to −2.34) and −1.83 mm Hg (95% CI, −2.35 to −1.31), respectively.
The CVD risk reduction associated with casual office measures has been estimated by Ettehad et al 9 with a meta-analysis of randomized drug trials (normalized with observational data); for every 10 mm Hg reduction in SBP, the risk of major cardiovascular disease events is reduced by 20% (relative risk [RR], 0.80; 95% CI, 0.77-0.83), coronary heart disease is reduced by 17% (0.83; 0.78-0.88), stroke reduction by 27% (0.73; 0.68-0.77), heart failure by 28% (0.72; 0.67-0.78), and a reduction in all-cause mortality by 13% (0.87; 0.84-0.91). Similar estimates for reduction in CVD risk are not readily available for 24-hour mean reductions in SBP, but, given that 24-hour mean BP better predicts CVD risk, 10 one might expect the reductions observed by both Ferdinand et al and Kario et al to confer greater reduction in CVD events in comparison with casual office readings.
Both Ferdinand et al and Kario et al report SBP reductions that nearly double the mean reductions from the Baker et al meta-analysis. Kario et al provided a discussion of the differences in the magnitude of reduction in BP between Japanese subjects in the current report with those observed in the EMPA-REG OUTCOME study (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). 11 There are insufficient data to fully explain why the 2 special populations treated with SGLT-2 inhibitors enjoy clinically more robust BP reductions. It is noteworthy, however, that both groups of investigators sought a special population believed to be more responsive to natriuresis when designing their trials. Although there are many differences between Japanese subjects residing in Japan and blacks, they do converge on a phenotype of salt sensitivity, elevated nighttime SBP, and excess hypertensionrelated cardiovascular risk.
In summary, EMPA has been associated with CVD risk reduction in patients with DM at high cardiovascular risk. The mechanism of this benefit has not been fully elucidated. In the reports from Kario et al and Ferdinand et al in this issue of Circulation, the authors identify populations with a phenotype of hypertension that appears to enjoy clinically significant BP reduction, an accepted proxy for reduction in CVD event rates. Although SGLT-2 inhibitors are not currently considered first-line agents in the treatment of DM in the general population, it may be time to rethink the approach to patients with both hypertension and DM. There are a number of agents that confer similar reductions in glycemic control. However newer agents, incretins (laraglutide and semagluitide), SGLT-2 inhibitors (canaglifozin and dapaglifozin), and a SGLT-1/2 inhibitor (sotagliflozin) are currently engaged in randomized trials assessing CVD events in patients with and without DM. Results from these trials may challenge conventional recommendations for diabetes management. Although admittedly additional data are needed on the SGLT-2 drug class in terms of both safety and efficacy, certain subgroups (those with salt sensitivity) may benefit from rethinking the current strategy of preferring glycemic agents with much less promise for CVD risk reduction when treating patients with both hypertension and DM.
